XPENG is ushering in 2026 with transformative momentum, reinforcing its strategic evolution into an AI-driven global technology leader. The company unveiled its next-generation flagship model, ...
Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback